Articles tagged with Cancer Patients
A study found that variations in the TANC1 gene are associated with a greater risk of radiation-driven side effects in prostate cancer patients. The research team developed a predictive genomic test to optimize treatment plans, allowing for improved quality of life for many cancer survivors.
A study published in Nature Communications found that pseudogene expression profiles can help explain how cancer occurs and aid in discovering new biomarkers. This knowledge is crucial for developing targeted therapies and predicting patient outcomes.
A study found that trials with broader age limits resulted in a significant increase in teenage cancer patients participating in clinical trials. The study showed a 13% rise in 15-19 year old patients and a 5% rise in 20-24 year olds, as well as an increase in children under 14 taking part in trials.
Researchers from Case Western Reserve University report a high degree of satisfaction among caregivers who received support teams for terminal cancer patients. The intervention improved satisfaction in five areas: pain relief, managing pain, speed in treating symptoms, information about side effects, and coordination of care.
A new approach identified two mutated tumor targets, KIF2C and POLA2, that play important roles in cell proliferation and may stimulate immune responses. This study provides a technical solution to identify mutated tumor targets for adoptive T-cell therapy, which has shown promise in treating metastatic melanoma.
A recent study published in Annals of Internal Medicine found that current standard medical guidelines for childhood cancer survivors can be reduced, saving large cost-savings and little reduction in overall quality of patient care. The study suggests that screenings can be safely done cost-effectively and improve the quantity of patie...
A new study found that HIV-infected people diagnosed with early-stage cancer are two to four times more likely to receive inadequate treatment. The research suggests that a lack of clinical trial data and guidelines on treating HIV patients with cancer may contribute to this disparity.
A recent study published in Nature Genetics has discovered a single gene that defines the difference between fast-growing, aggressive tumors and slow-growing, non-aggressive ones. The gene mutation GTF2l was found to be present in almost all indolent forms of thymoma, suggesting potential implications for treatment.
Researchers identified two antidepressant classes, including the alpha-2-adrenergic receptor antagonist Mianserin, that improve symptoms of depression in cancer patients. However, these treatments may be less well-tolerated due to potential side effects.
Researchers have developed a therapeutic vaccine targeting mutant IDH1, a common genetic mutation in brain tumors. The vaccine was tested on mice and showed promising results, with immune cells recognizing and attacking cancer cells. A clinical trial is planned to test the safety of the vaccine in human patients.
A team of researchers at UT Arlington has developed a low-cost, non-invasive device to detect bladder cancer cells in urine. The device uses nanotechnology and can identify as few as two cancer cells in a full liter of urine, making it a promising tool for early detection.
A recent study published in Cancer suggests that family dysfunction is a strong predictor of emotional problems in children of cancer patients. The research analyzed data from 235 families and found that general family dysfunction was the best predictor of emotional and behavioral symptoms in children.
The foundation has committed nearly $49 million to support the careers of 77 physician-scientists across the US since 2000. The Clinical Investigator Award program aims to address the shortage of physicians capable of translating scientific discovery into new cancer breakthroughs.
Researchers discover distinct mutational signature and nine significantly mutated genes associated with nasopharyngeal cancer. The findings provide an enhanced road map for studying the molecular basis of this disease, which has limited understanding compared to other cancers.
A new tool, COST (COmprehensive Score for financial Toxicity), measures a patient's risk for and ability to tolerate financial stress in cancer care. The study found that financial toxicity affects 30% of cancer survivors, with significant impact on workability and quality of life.
Researchers have developed a clinically relevant mouse model for squamous cell lung cancer, driven by the misregulation of genes sox2 and lkb1. The discovery uncovers new treatment strategies and provides insights into potential targeted therapies.
A study of over 56,000 patients with inflammatory bowel disease found no association between TNF inhibitor use and increased cancer risk. However, the authors emphasize the need for continued long-term follow-up to monitor potential risks.
A study of over 59,000 patients found that 3D digital breast tomosynthesis increased overall cancer detection by 28.6% and invasive cancer detection by 43.8%. The technology also reduced recall rates in community-based radiology practice.
Researchers are testing the safety and effectiveness of AG-120, a new drug designed for patients with IDH1 gene mutations, in a clinical trial at the Virginia G. Piper Cancer Center Clinical Trials. The study aims to improve treatment options for patients with solid tumors, including brain tumors and gallbladder bile duct cancer.
The AMEN protocol provides a script to help doctors and nurses talk to dying patients and families about their hopes for a miracle. This approach aims to respect patients' beliefs and values while maintaining trust and open communication, even when discussing futile treatments.
A recent study found that most elderly women with non-metastatic breast cancer comply with hormone therapy recommendations. However, non-white women were more likely to discontinue treatment, highlighting a need for targeted interventions.
Researchers found that combining low doses of bortezomib with an oncolytic virus significantly improves the ability to kill cancer cells. The combination treatment suppressed tumor growth by 92% in a glioma model and improved survival rates, offering a novel therapeutic strategy for solid tumors.
New research links low blood cholesterol to more advanced tumor stages and reduced cancer survival rates in kidney cancer patients. High cholesterol levels are associated with a lower risk of death from the disease, suggesting a potential new prognostic tool for monitoring patient outcomes.
The Phase 2B clinical trial of CRS-207 and GVAX Pancreas vaccines aims to improve treatment outcomes for patients with advanced pancreatic cancer. The combination regimen shows promise in improving survival rates, with no serious treatment-related adverse side effects.
Researchers at UNC have found that Set2 plays a crucial role in DNA repair, which can lead to the development of cancer cells if impaired. The discovery offers insights into creating more targeted therapies for various forms of cancer.
Researchers found that early palliative support services significantly reduced depression and feelings of overwhelm among family caregivers, improving overall quality of life. The study suggests that timely intervention can better equip caregivers to cope with the demands of caring for patients with advanced cancer.
Researchers found that fasting can replenish stem cells in the blood, combating chemotherapy-induced and aging-related changes in immune cell function. Fasting has also been shown to rejuvenate the immune system of old mice and protect against white blood cell loss in human patients.
A new drug called MM-398 has shown a significant overall survival rate in patients with advanced pancreatic cancer when given in combination with 5-flourouracil and leucovorin. The study achieved an overall survival of 6.1 months, a 1.9 month improvement over the control arm.
A recent study suggests that expanded health coverage under the Affordable Care Act (ACA) may lead to better cancer outcomes for young adults. The study found that patients with insurance coverage were more likely to receive definitive therapy and had a higher survival rate compared to uninsured individuals.
The challenges in cancer molecular testing require effective communication between oncologists and pathologists. Close communication, systems approaches, and new institutional protocols can help ensure efficient testing and optimal patient outcomes.
Researchers have found that crizotinib produces significant responses in patients with intermediate and high MET amplification, resulting in a 60-67% overall objective response rate. The drug showed early activity against MET-dependent cells in preclinical laboratory studies.
A non-invasive breath test has been developed to detect lung cancer by analyzing volatile organic compounds in exhaled breath. The device can distinguish between patients with lung cancer and chronic obstructive pulmonary disease (COPD), as well as define the stage of any present cancer.
Researchers report promising results from a phase I study on MPDL3280A, an investigational drug for treating advanced bladder cancer. The trial showed improved response rates among patients with PD-L1-positive tumors, with 7% achieving complete responses.
Research identifies new ways to ease cancer therapy effects and enhance patient well-being, from fertility preservation techniques to earlier palliative care. Studies show improved survival rates and reduced side effects for certain treatments.
A phase 3 study found that ibrutinib significantly lengthened progression-free survival as a second-line therapy for CLL, with 86% of patients on ibrutinib experiencing durable responses. Ibrutinib also showed superior results compared to ofatumumab in terms of overall survival and partial response rates.
The American Society for Clinical Oncology has released new clinical guidelines for cancer-related fatigue, developed in collaboration with Moffitt Cancer Center. The guidelines recommend regular screening and treatment of fatigue in cancer patients after treatment, as well as addressing other contributing factors such as depression, p...
Researchers at Fox Chase Cancer Center halted a trial after 23% of patients experienced severe cardiovascular events while receiving a chemotherapy regimen. The study aimed to investigate the effectiveness and safety of gemcitabine and cisplatin in patients with muscle-invasive bladder cancer.
Researchers at Fox Chase Cancer Center found that genetic mutations in three specific genes can predict which bladder cancer patients will benefit from early chemotherapy. Patients with these mutations are more likely to respond to treatment and have a higher chance of being cancer-free after surgery.
Chronic kidney disease is associated with a higher risk of developing renal and urothelial cancers. A recent study found that patients with reduced glomerular filtration rates were more likely to develop these types of cancer, particularly those with severe chronic kidney disease.
A retrospective study of over 1.2 million adults found that reduced glomerular filtration rate is an independent risk factor for renal and urothelial cancer, but not other types of cancer. Lower GFR levels were associated with increased rates of incident renal cancer and urothelial cancer.
A new study has discovered how ibrutinib resistance develops in CLL patients, identifying key gene mutations that weaken the drug's ability to bind with Bruton's tyrosine kinase. This understanding is crucial for developing effective alternative treatments for patients who develop resistance.
The USPSTF recommends screening for hepatitis B virus (HBV) in nonpregnant high-risk adolescents and adults, as well as postnatal immunoprophylaxis to prevent maternal transmission. Studies have shown that these interventions can reduce mortality and hospital readmissions related to heart failure.
Researchers discovered uric acid's role as a major intracellular antioxidant that prevents oxidative stress and its impact on cancer and aging. The p53-GLUT9 pathway is a mechanism to prevent ROS accumulation, which causes cell damage.
A recent study highlights the challenges faced by refugees from Iraq and Syria in accessing affordable cancer treatment, with host countries struggling to find the money and medicine. Innovative financing schemes are needed to improve access to quality care for these patients.
Research suggests that patients with polycystic kidney disease (PKD) who undergo a kidney transplant may be less likely to develop cancer compared to those without PKD. The study found that PKD patients were 16% less likely to develop cancer than others who received a kidney transplant, and their overall cancer risk was 48% lower than ...
Researchers used computer simulations to identify most effective drugs for brain cancer, considering genomic signatures and predicted sensitivities. The approach may help personalize therapies for cancer patients, selectively testing effective drugs while reducing exposure to toxic ones.
A systematic review compared the efficacy and safety of radiofrequency ablation (RFA) and complete endoscopic resection (EMR) for dysplastic Barrett's esophagus. Both treatments were found to be effective in short-term treatment, but RFA had lower short-term adverse event rates. Long-term esophageal strictures were more common with EMR.
A study of 2,290 women with breast cancer found that while many consider or undergo contralateral prophylactic mastectomy (CPM) to prevent cancer in the other breast, most do not have a clinically significant risk. The procedure is often associated with genetic testing, family history, and higher education.
Circadian rhythm disruption during chemotherapy worsens its side effects, including fatigue and body weight loss. Researchers suggest personalising chronotherapy delivery to improve clinical tolerability and potentially boost treatment effectiveness.
The Gordon Sondland and Katherine Durant Foundation has donated $1 million to the Oregon Health & Science University's Knight Cancer Institute to establish an annual research conference, drawing top thought leaders in cancer treatment. The conference aims to accelerate breakthroughs in early detection and treatment.
Researchers found distinct profiles of bacteria in saliva that may indicate early-stage pancreatic cancer diagnosis. High levels of Leptotrichia and Campylobacter were detected in patients with pancreatic cancer compared to healthy controls.
Dr. Neal Meropol, Chief of Hematology and Oncology at Case Western Reserve University, is honored as an ASCO Fellow for his exceptional volunteer service and dedication to cancer care. He has served on the ASCO Board of Directors and various committees, contributing to the organization's mission to improve cancer care.
A team of scientists has identified cancer stem cells in patients with myelodysplastic syndromes, a malignant blood condition that frequently develops into acute myeloid leukemia. The study provides conclusive evidence for the existence of cancer stem cells and suggests that targeting these cells could lead to effective treatment.
A new chemotherapy regimen administered before surgery and chemoradiation improves tolerance to treatment in most rectal cancer patients. The study found that over 90% of patients were able to complete a full course of standard treatment, with many experiencing a significant reduction in symptoms.
A new study from Penn Medicine's Abramson Cancer Center found that inappropriate cancer patient demands are uncommon and rarely lead to unnecessary tests and treatments. Most clinicians believe most patient requests are appropriate and incorporated into suitable treatment plans.
A 1993 trial found no survival advantage in second look surgery for colorectal cancer patients with high CEA levels. The new analysis confirms this finding, despite methodological changes over the past two decades.
A recent study published in Pediatrics suggests that children exposed to a parent's nicotine-dependent smoking are at a higher risk of becoming heavy smokers themselves. Parental smoking cessation early on is crucial to prevent habitual smoking in the next generation.
Researchers at Ohio State University have developed a novel strategy for treating multiple myeloma by genetically modifying T lymphocytes to target the CS1 molecule on myeloma cells. The modified cells were shown to efficiently destroy human multiple myeloma cells in laboratory studies and animal models.
A nationwide dataset analysis found that black women are 1.84 times more likely to be diagnosed with triple-negative breast cancer, a subtype with poorer prognosis. Asian/Pacific Islander women were also more likely to be diagnosed with HER2-overexpressing breast cancer.
Researchers identified potentially actionable mutations in cancers of the appendix using next-generation DNA sequencing. KRAS and GNAS mutations were found to be common alterations in both low-grade appendiceal mucinous neoplasm (LAMN) and adenocarcinoma tumors.